ATAI AtaiBeckley Inc.
Price Chart
Executive Summary
AtaiBeckley Inc. announced the peer-reviewed publication of positive Phase 2a data for its intranasal therapy BPL-003 in treatment-resistant depression (TRD), showing rapid and sustained symptom reduction after a single dose. The results support the planned initiation of Phase 3 trials in Q2 2026, following a successful FDA End-of-Phase 2 meeting. The drug has Breakthrough Therapy designation and demonstrated strong efficacy and tolerability in a small cohort.
Actionable Insight
Traders should monitor for Phase 3 trial design details and enrollment updates in Q2 2026, which could catalyze further upside. The strong Phase 2a signal in a difficult-to-treat population increases the probability of regulatory success and commercial potential, supporting a re-rating ahead of pivotal data.
Key Facts
- Phase 2a Cohort 1 data published in Journal of Psychopharmacology: 12 patients with TRD received a single 10 mg intranasal dose of BPL-003.
- Mean MADRS score reduction of 12.6 points by Day 2, sustained to Day 85 (mean score 14.5).
- 54.5% response rate (≥50% MADRS reduction) and 63.6% remission rate (MADRS ≤10) observed over 12 weeks.
- SHAPS scores improved from 8.4 to 1.5, indicating resolution of anhedonia.
- No serious adverse events; treatment well tolerated with only mild-to-moderate transient side effects.
- FDA Breakthrough Therapy designation granted for BPL-003 in TRD.
- Phase 3 program on track to initiate in Q2 2026.
Financial Impact
Non-dilutive, near-term value inflection expected ahead of Phase 3 initiation. No direct revenue or EPS impact yet, but de-risks clinical pathway for BPL-003.
Risk Factors
- Small sample size (n=12) limits generalizability.
- Open-label design introduces bias; placebo-controlled Phase 3 data needed.
- Development risk remains high for a novel psychedelic-based therapy.
- Future dilution likely as Phase 3 funding approaches.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256934 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
12d ago
|
8-K
| $4.53 $4.50 | ▼ −0.66% | ▼ −1.06% | $3.92 (−13.47%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.15 $4.24 | ▲ +2.17% | ▲ +1.59% | $3.92 (−5.54%) |
|
Apr 27, 2026
7w ago
|
Press Release
| $4.34 $4.33 | ▼ −0.23% | ▲ +0.25% | $3.92 (−9.68%) |
|
Apr 20, 2026
7w ago
|
144
| $4.87 $4.71 | ▼ −3.29% | ▼ −4.30% | $3.92 (−19.51%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $3.76 $3.70 | ▼ −1.60% | ▼ −2.17% | $3.92 (+4.26%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $3.38 $3.54 | ▲ +4.73% | ▲ +4.17% | $3.92 (+15.98%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $3.65 $3.56 | ▼ −2.47% | ▼ −1.07% | $3.92 (+7.40%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.14 $4.06 | ▼ −1.93% | ▼ −1.83% | $3.92 (−5.31%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $3.39 $3.89 | ▲ +14.75% | ▲ +13.90% | $3.92 (+15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access